Compare ARK Genomic Revolution ETF (ARKG) vs Wells Fargo & Co (WFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Wells Fargo & Co — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Wells Fargo & Co trades at $87.6 (market cap $266.73B). The key difference: Wells Fargo & Co pays a 2.07% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Wells Fargo & Co nearer its low. Which is the better fit depends on your goals.
| ARKG | WFC | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $96.40 |
52-Week Low | $23.09 | $73.42 |
Market Cap | — | $266.73B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Wells Fargo (WFC) trades at $87.12, up 0.24% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows steady revenue growth to $83.70B in 2025 and net income of $21.34B, with a P/E of 13.47 suggesting reasonable valuation. Recent news highlights anticipation for Q2 2026 earnings on July 14, 2026, with analysts expecting EPS of $1.73. The dividend of $0.45 per share was paid in June 2026, supporting income investors.
Outlook is cautiously optimistic with a consensus price target of $99.44, implying 14% upside, though risks include volatile cash flows and regulatory scrutiny. Earnings misses in recent quarters warrant monitoring, but improving net interest income and fee growth could drive positive surprises. Investor sentiment is balanced with 45% buy ratings, but macroeconomic pressures on banks remain a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
